Pacific Biosciences Of California (PACB) EPS (Weighted Average and Diluted) Growth (3y) (2022 - 2026)
Pacific Biosciences Of California (PACB) EPS (Weighted Average and Diluted) Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | -6.66% |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | 7.81% |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | -1.10% |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | 62.43% |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | 10.44% |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | 27.51% |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | 61.98% |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | 6.01% |
| 10 | Pacific Biosciences Of California | 402.15 Mn | 126.19 Mn | 12.84 Mn | 56.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.32% |
| Dec 31, 2025 | 29.44% |
| Sep 30, 2025 | 27.42% |
| Jun 30, 2025 | 24.09% |
| Mar 31, 2025 | -57.30% |
| Dec 31, 2024 | -10.06% |
| Jun 30, 2024 | -44.98% |
| Mar 31, 2024 | 13.62% |
| Dec 31, 2023 | -38.80% |
| Sep 30, 2023 | -22.92% |
| Jun 30, 2023 | -23.13% |
| Mar 31, 2023 | -236.20% |
| Mar 31, 2022 | -22.76% |